Why the study?
Anticoagulant therapy is essential in pregnant women with mechanical heart valves to prevent valve thrombosis, but the risk of bleeding complications has not gained much attention.
Does the choice of anticoagulant regimen affect the risk of peri-partum and post-partum bleeding in pregnant women with mechanical heart valves?
Does the choice of anticoagulant regimen affect the risk of peri-partum and post-partum bleeding in pregnant women with mechanical heart valves?
Bleeding is common during pregnancy in women with mechanical heart valves, with VKA monotherapy or UFH+VKA showing the lowest bleeding risk compared to LMWH-based regimens.
Answers are grounded in this paper and cite their sources.
May support VKA-based regimens to minimize bleeding; leaves open randomized confirmation in pregnant women with mechanical valves.
Anticoagulant therapy is essential in pregnant women with mechanical heart valves to prevent valve thrombosis. The risk of bleeding complications in these patients has not gained much attention. This systematic review and meta-analysis investigate the prevalence of bleeding peri-partum and post-partum in women with mechanical heart valves and also investigate whether bleeding risk differed across anticoagulant regimens or according to delivery mode. The present study was conducted according to The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. Studies reporting bleeding prevalence in pregnant women with mechanical heart valves receiving anticoagulant therapy were identified through PubMed and Embase on December 08, 2021. Data on bleeding complications, delivery mode, and anticoagulation therapy were extracted. A total of 37 studies were included, reporting 423 bleeding complications in 2,508 pregnancies. A meta-analysis calculated a pooled prevalence of 0.13 (95% confidence interval [CI]: 0.09-0.18) bleeding episodes per pregnancy across anticoagulant regimens. The combination of unfractionated heparin (UFH) and vitamin K antagonist (VKA) and single VKA therapy showed the lowest risk of bleeding (8 and 12%). Unexpectedly, the highest risk of bleeding was found in women receiving a combination of low-molecular-weight-heparin (LMWH) and VKA (33%) or mono-therapy with LMWH (22%). However, this could be dose related. No difference in bleeding was found between caesarean section versus vaginal delivery (p = 0.08). In conclusion, bleeding episodes are common during pregnancy in women with mechanical heart valves receiving anticoagulant therapy. A combination of UFH and VKA or VKA monotherapy showed the lowest risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Jakobsen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: